LMTMay 17, 2026 at 2:16 PM UTCCapital Goods

Defense Supercycle Confirmed, But Execution Gaps Keep Lockheed Martin in Wait Mode

Read source article

What happened

The FY27 defense budget nearly doubles Research & Procurement spend, with Lockheed's core programs like F-35, PAC-3/MSE, and THAAD seeing massive increases, yet the company's Q1 2026 free cash flow was negative $291 million as Aeronautics fixed-price losses persisted and backlog fell $7.2B quarter-over-quarter to $186.4B. Supply chain disruptions, tariffs, and rare earth shortages from the Strait of Hormuz closure add margin headwinds, while contract assets swelled $2.9B due to slower F-35 billing. The $63B in backlog recognizable over 12 months provides near-term revenue visibility, but cash conversion remains gated by definitization of munitions orders and acceptance of deliveries. At $513.9 (24.7x P/E), the stock already prices in management's FY26 FCF guide of $6.5–$6.8B, leaving no room for further execution stumbles. Demand headlines alone are insufficient; the investment case now hinges on observable proof of cash flow normalization and backlog stabilization over the next two quarters.

Implication

The defense supercycle provides a multi-year demand tailwind, but near-term margins face headwinds from supply chain, tariffs, and rare earth shortages, while Q1's negative FCF underscores working capital drag. The $63B recognizable backlog in 12 months offers a buffer, but investors should demand sequential improvement in Aeronautics unfavorable adjustments (Q1 baseline: $210M combined on F-16 and C-130) and progress on PAC-3 definitization before re-engaging. Trim above $590; attractive entry below $480.

Thesis delta

The news quantifies the supercycle demand but reinforces that margin headwinds and cash conversion issues are more explicit than previously appreciated. The thesis shifts from 'demand is booming' to 'demand is booming, but near-term execution friction and supply constraints cap upside until proven otherwise.' The WAIT rating remains unchanged; the stock needs to show cash generation momentum, not just backlog growth.

Confidence

moderate